Amyloid beta 42 oligomer (Aβ42 oligomer)

Amyloid beta 42 oligomers are *soluble, aggregated forms* of the 42-amino-acid Aβ peptide, derived from the sequential cleavage of amyloid precursor protein by β- and γ-secretases[6]. Unlike mature amyloid plaques, which are largely composed of insoluble fibrils, Aβ42 oligomers remain soluble and are now widely believed to be the *primary neurotoxic agents* in Alzheimer's disease[2][6][8]. These oligomers can exist as pentamers, hexamers, dodecamers, and higher-order assemblies; their dynamic and heterogeneous structure makes precise characterization challenging[1][3][7]. They can disrupt synaptic integrity, form pathogenic membrane pores, induce neuroinflammation, and accelerate neuronal death. Structurally, they feature a rich composition of β-sheet motifs and assemble into various morphologies, including concentric β-barrels and annular protofibrils[1][5][7]. Recent therapeutic strategies focus on directly neutralizing or eliminating these oligomers using antibody-based drugs, small-molecule inhibitors, or advanced nanomaterials, offering promising avenues for disease modification especially as traditional plaque-targeting therapies have not yielded substantial clinical improvement[2][8]. Detection of Aβ42 oligomers in cerebrospinal fluid is a developing biomarker for early diagnosis and patient stratification. The central challenge in targeting Aβ42 oligomers lies in their *structural diversity, transient nature,* and the risks associated with manipulating amyloid pathways in the brain[8].

Other names

amyloid-β(1–42) oligomerAβ42 oligomeramyloid beta (1–42) oligomerAβOsbeta-amyloid 42 oligomeramyloid beta 42 aggregate

Neutralization/degradation of soluble oligomers via antibody binding[2][8]; Inhibition of oligomer aggregation and downstream fibril formation[2][8]; Blockade of membrane interaction to prevent neurotoxicity and synaptic loss[8]; Disaggregation or sequestration using nanoparticle delivery systems[2]